However, another study has shown clinical benefit in a pair of siblings with recurrent GBM having biallelic mismatch repair deficiency, wherein treatment with the PD-1 inhibitor nivolumab showed significant clinical and radiological responses [12]. Here, PDCD1 is linked to glioblastoma.